Status:

ACTIVE_NOT_RECRUITING

SKY Breath Intervention

Lead Sponsor:

University of California, San Francisco

Conditions:

Depression

Anxiety Disorders

Eligibility:

All Genders

16-24 years

Brief Summary

Depression is highly debilitating and prevalent among adolescents. Adolescent-onset depression is associated with long, severe, and recurrent episodes that are often not responsive to treatment. There...

Detailed Description

Participants \& Screening: All participants (16-24yrs) will be first screened for COVID and only those who are negative will be allowed to enroll. Participants who meet the criteria for the study at i...

Eligibility Criteria

Inclusion

  • adolescent participants ages 16-24 yrs old (NIH defines adolescents as up through age 24 years old)
  • mild-to-moderate depression with the BDI-II score greater than or equal to 14 (Smarr and Keefer 2011)
  • technologically able (Zoom);
  • nonpractitioners of daily meditation/breath-work.

Exclusion

  • pregnant or lactating females
  • metal implants unsafe for MRI
  • current or lifetime diagnosis of schizophrenia, schizoaffective, bipolar on lithium, or seizure disorders
  • recent surgical patient (within 6 months)
  • substance use disorder within the last 1 year
  • history of significant medical conditions (e.g. traumatic brain injury)
  • suicidal ideation (SI) with intent and/or plan to harm self (SI without intent and/or plan to harm self will be allowed to enter the study)

Key Trial Info

Start Date :

April 22 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2028

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT05388110

Start Date

April 22 2022

End Date

December 1 2028

Last Update

May 15 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California, San Francisco

San Francisco, California, United States, 94143